Equities

Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.95
  • Today's Change0.00 / 0.00%
  • Shares traded56.05k
  • 1 Year change+6.74%
  • Beta0.5920
Data delayed at least 20 minutes, as of Jun 07 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.

  • Revenue in AUD (TTM)1.44m
  • Net income in AUD-5.90m
  • Incorporated2014
  • Employees--
  • Location
    Proteomics International Laboratories LtdHarry Perkins Institute, 6 Verdun StreetNEDLANDS 6009AustraliaAUS
  • Phone+61 89389-1992
  • Fax+61 86151-1038
  • Websitehttps://www.proteomics.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biome Australia Ltd10.24m-2.86m71.30m30.00--33.07--6.96-0.0141-0.01410.05060.01011.371.936.04341,434.70-38.27---74.60--61.29---27.97--0.9514-15.920.4032--73.58--32.20------
Neurotech International Ltd1.28m-4.98m72.23m----13.21--56.55-0.0058-0.00580.00150.00540.1826-0.11495.67---71.23-197.33-74.66-255.24100.0779.57-390.03-1,043.8818.35--0.00--106.2283.24-131.75------
Percheron Therapeutics Ltd624.51k-10.85m73.03m8.00--4.44--116.93-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
Next Science Ltd33.44m-24.53m75.84m----3.92--2.27-0.106-0.1060.14290.06631.467.478.33---107.19-74.40-136.06-90.3173.2076.98-73.36-128.263.45-50.370.0698--89.3650.80-28.29---2.28--
Orthocell Ltd6.06m-7.42m76.40m----33.39--12.62-0.0369-0.03690.03010.01090.21821.5027.68---26.73-32.67-31.96-38.5377.1163.04-122.55-374.464.36--0.2586--215.2451.5331.39--11.07--
Actinogen Medical Ltd337.51k-14.87m77.78m----5.66--230.45-0.0073-0.00730.00020.00510.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
PharmAust Limited1.85m-7.79m83.14m52.00--10.53--44.92-0.0236-0.02010.00550.020.1977--6.71---83.26-25.56-96.46-28.7820.0690.73-421.04-59.16---104.650.00---13.533.42-263.63---47.47--
Paradigm Biopharmaceuticals Ltd8.67m-69.00m87.45m----2.60--10.09-0.2296-0.22960.02880.09620.1298--2.25---103.34-40.96-127.58-44.1399.87---796.30-466.85---348.760.0085--7.5825.42-32.26------
Argenica Therapeutics Ltd92.21k-4.67m94.57m----11.58--1,025.59-0.0511-0.05110.0010.06650.0109--0.6384---55.31---69.00-------5,067.62-----6,663.200.00--2,340.00---17.71------
Recce Pharmaceuticals Ltd6.81m-11.32m119.33m----223.08--17.52-0.0637-0.06370.03850.00261.68--52.84---279.04-110.82-985.91-139.61-----166.11-391.79---24.070.2712--39.5327.79-19.03---26.31--
Vita Life Sciences Limited74.16m9.08m125.42m124.0013.552.9213.081.690.1660.1661.360.76951.332.347.35--16.2715.2522.5121.9958.1460.9012.2411.712.29--0.008939.0510.8812.5028.1830.0712.1519.14
Arovella Therapeutics Ltd139.02k-10.23m126.02m14.00--34.84--906.48-0.0127-0.01270.00020.00340.0249--15.15---182.82-77.12-276.07-93.2683.5663.41-7,357.19-1,471.57----0.00--45.470.3491-18.11---68.72--
Proteomics International LaboratoriesLtd1.44m-5.90m126.97m----22.18--87.87-0.0518-0.05180.01290.04370.1817--11.13---75.75-57.79-87.11-67.57-----416.78-229.69---283.470.0088---14.644.12-24.20--89.02--
Data as of Jun 07 2024. Currency figures normalised to Proteomics International Laboratories Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

6.04%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 25 Jan 20247.90m6.04%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.